Gilead's HIV Prevention Shot Achieves 100% Efficacy in Trials
TL;DR
Gilead Sciences announced that its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy in preventing HIV infections in cisgender women during the Phase 3 PURPOSE 1 trial. The independent Data Monitoring Committee recommended stopping the blinded phase of the trial and offering open-label lenacapavir to all participants. This marks the first Phase 3 HIV prevention trial to show zero infections, highlighting lenacapavir's potential as a significant new tool for HIV prevention.
- Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention Gilead Sciences
- Gilead Shot Prevents 100% of HIV Cases in Trial of African Women Bloomberg
- Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial CNBC
- Gilead Stock Surges on Strong Results in HIV Drug Study Investopedia
- Gilead says its HIV prevention shot was 100% effective in a clinical trial Quartz
Want the full story? Read the original reporting
Read on Gilead Sciences